Skip to main content

Table 1 Novel autoantibodies of potential diagnostic relevance in rheumatoid arthritis

From: Autoantibodies in rheumatoid arthritis and their clinical significance

Antibody (year)

Antigen (year)

Sensitivity (%)

Specificity (%)

References

Antikeratin (1979)

Filaggrin (1993)

40

92–99

[49]

 

Anticitrullinated peptides (1998) = deiminated arginine identified in filaggrin (1999) and in fibrin (2001)

53*

96

[8, 1013]

Anti-RA33 (1989)

hnRNP-A2 (1992)

32

90–96

[6, 1421]

Anti-Sa (1994)

50 kDa protein, unidentified

42

98

[11, 20, 22, 23]

Anti-p68 (1995)

BiP/grp78 (2001)

40

96

[24, 25]

  1. BiP, immunoglobulin binding protein; grp78, glucose-regulated protein 78 kDa; hnRNP-A2, heterogeneous nuclear ribonucleoprotein A2. * In rheumatoid factor-negative patients, approximately 15%. Specificity of anti-RA33 when a diagnosis of systemic lupus erythematosus (SLE) or mixed connective tissue disease (MCTD) can be excluded, or in the absence of autoantibodies associated with SLE or MCTD (anti-DNA, anti-Sm, anti-U1 RNP, anti-Ro, anti-La).